FDA Safety Review of GnRH Agonists Used To Treat Prostate Cancer

[Guest guest]

The FDA has announced that it is conducting an ongoing safety review of gonadotropin-releasing hormone agonists (GnRH) to address evidence that suggests an increased

risk for diabetes and cardiovascular disease in men with prostate cancer who are treated with these drugs.

The "FDA became aware of the potential safety risk after several studies were published suggesting a small, statistically significant increase in the risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications," explained a V. Jefferson, a press officer at the FDA. "As data emerged identifying these safety signals in this class of medications, the FDA believed it

was important to conduct a review and communicate preliminary findings to the public."Click on the below link for the full story:<http://www.medscape.com/viewarticle/721203>